41-14 Jensen Heads Oncology Care at Scripps Health

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Jensen Heads Oncology Care at Scripps Health; Portteus Named President, CEO of LIVESTRONG Foundation

KAREN JENSEN joined Scripps Health as director of the oncology clinical care line for the health system’s integrated cancer program.

For the past 21 years, Jensen held a variety of leadership roles in Mayo Clinic’s southwest Minnesota region. Most recently, she was vice president of quality and director of clinical outcomes, where she was responsible for improving quality and safety across patient care, including the implementation of a regional medical staff quality program.

Previously at Mayo Clinic, she served as vice president of organizational performance, learning and innovation; vice president of operations; chief financial officer; and director of patient flow.

CHANDINI PORTTEUS was named president and CEO of LIVESTRONG Foundation.

Portteus most recently served as chief mission officer at Susan G. Komen For The Cure, where she was instrumental in creating initiatives involving more than 30 countries. Her global programming work included fundraising with major donors and partnerships Fortune 100 companies.

In addition, she was the architect and relationship manager for the scientific advisory bodies of Susan G. Komen, which included the Scientific Advisory Board and the Komen Scholars.

Previously, she worked in sales for Knoll Pharmaceutical, as well as conducting clinical research at UT Southwestern Medical School, Children’s Medical Center, UT Houston School of Public Health and Parkland Hospital.

MARGARET HAMBURG, former commissioner of FDA, was appointed foreign secretary of the Institute of Medicine.

In this part-time position, Hamburg will serve as a senior advisor on international matters to the IOM president and council and as liaison to foreign academies of medicine and science. Her term is effective through June 30, 2019.

She succeeds Jo Ivey Boufford, president of the New York Academy of Medicine, who served in the position for eight-and-a-half years.

Hamburg was appointed commissioner of the FDA in May 2009, the second woman to serve in this position. Her past roles have also included senior scientist at the Nuclear Threat Initiative; assistant secretary for policy and evaluation in the Department of Health and Human Services; and commissioner of the New York City Department of Health and Mental Hygiene.

Hamburg is the daughter of David Hamburg, who served as president of the IOM from 1975 to 1980. Since her election to the IOM membership in 1994, she has actively contributed to the mission of the IOM as chair of the Board on Global Health (2005-2009) and as a member of the IOM Council (2005-2009) and various consensus and convening activities.

THE NCCN FOUNDATION awarded its fifth series of Young Investigator Awards to six oncology researchers from NCCN Member Institutions.

The awards provide grants of $150,000 over a two-year period for research initiatives focused on assessing and improving outcomes in cancer care, beginning in July. The studies will be managed and overseen by the NCCN Oncology Research Program.

The awards were made possible through support from AbbVie, Amgen, Genentech, Gilead, Merck, Millennium, Pfizer and Sigma-Tau.

The award recipients and their studies are:

James Blachly, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, for “Genomic Stratification and Prognostication of Adult Acute Myeloid Leukemia by Combination Mutation Status.”

Roisin Connolly, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, for “Harnessing the Immune System to Treat Breast Cancer: Novel Mechanisms of Resistance and Treatment Strategies.”

Areej El-Jawahri, of Massachusetts General Hospital Cancer Center, for “A Multimodal Intervention to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant Survivors.”

Douglas Johnson, of Vanderbilt-Ingram Cancer Center, for “Survivorship in Patients Receiving Immune Checkpoint Inhibitors.”

Todd Morgan, of the University of Michigan Comprehensive Cancer Center, for “Tissue-Based Genomics for Risk Stratification in Localized Renal Cell Carcinoma.”

Alpa Nick, of MD Anderson Cancer Center, for “Matched Pair Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination with Chemotherapy in Frontline Ovarian Cancer.”

CHRISTINA COUGHLIN was named chief medical officer of Immunocore Ltd.

Most recently, Coughlin was leading two early development programs at Novartis in checkpoint inhibition and PI3 kinase inhibition. She led the overall program early development teams, including preclinical pharmacology, toxicology, clinical pharmacology, clinical development, biomarker development and regulatory work.

Before that, she served as international project team leader at Morphotek Inc., where she led the early clinical development team responsible for monoclonal antibody development against novel targets.

GERRIT LOS was named vice president of pharmacology at AnaptysBio Inc.

Los will lead translational biology across the company’s antibody pipeline, including programs focused in immuno-oncology. Los will report to Macro Londei, AnaptysBio’s chief development officer.

Los joins AnaptysBio from Five Prime Therapeutics, where he led translational medicine across several immuno-oncology related biologics. Prior to Five Prime, Los was head of cancer biology at Pfizer, where he directed teams responsible for the development of several targeted cancer therapeutics, including crizotinib, axitinib and palbociclib.

Prior to Pfizer, Los was an adjunct professor at the University of California San Diego where his work focused on identifying response markers in cancer.


President Joe Biden’s proposed Advanced Research Projects Agency-Health would be a welcome partner to NCI—particularly in conducting large, collaborative clinical investigations, NCI Director Ned Sharpless said.“I think having ARPA-H as part of the NIH is good for the NCI,” Sharpless said April 11 in his remarks at the annual meeting of the American Association for Cancer Research. “How this would fit with the ongoing efforts in cancer at the NCI is still something to work out.”